A case of chronic eosinophilic pneumonia in a patient treated with dupilumab

Francesco Menzella, Gloria Montanari, Giulia Patricelli, Alberto Cavazza, Carla Galeone, Patrizia Ruggiero, Diego Bagnasco, Nicola Facciolongo

Research output: Contribution to journalArticle

Abstract

The increasing knowledge on inflammatory pathways has driven the development of targeted biological therapies for severe refractory asthma. Among the recently developed biologics, the fully human monoclonal antibody dupilumab is an interesting therapeutic option, given its ability to inhibit the biological effects of both IL-4 and IL-13. We describe the case of a male, Caucasian, 56-year-old patient with allergic and eosinophilic severe asthma. Given the poor asthma control, he started treatment with add-on dupilumab, and after the tenth injection, he presented with a fever and bilateral pulmonary thickening. A significant increase in blood eosinophilia was also reported. The patient underwent a fiberoptic bronchoscopy with bronchoalveolar lavage (BAL) and transbronchial lung biopsy (TBLB/TBB). BAL revealed eosinophils alveolitis (60%) while TBB showed findings compatible with chronic eosinophilic pneumonia (CEP). After prolonged treatment with oral corticosteroids, the clinical picture improved with resolution of CEP. Since the beginning of dupilumab treatment, simultaneously to a great improvement in asthma control, the patient showed a progressive increase in blood eosinophils count and subsequent onset of clinical-radiological pattern suggestive of CEP. Based on published data, dupilumab may have induced an alteration of the complex immunological pathway of our patient. This pathway is affected by both allergic and eosinophilic asthmatic endotypes, and consequently, the concomitant action of allergenic stimuli and eosinophils may have caused the appearance of eosinophilic pneumonia. To our knowledge, this is the first reported case of CEP as a possible severe side effect of dupilumab administration.

Original languageEnglish
Pages (from-to)869-875
Number of pages7
JournalTherapeutics and Clinical Risk Management
Volume15
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Blood
Asthma
Monoclonal antibodies
Eosinophils
Biopsy
Caucasian
Refractory materials
Bronchoalveolar Lavage
stimulus
Pulmonary Eosinophilia
ability
Lung
Biological Therapy
Interleukin-13
Eosinophilia
Bronchoscopy
Therapeutics
Biological Products
Interleukin-4
Adrenal Cortex Hormones

Keywords

  • Dupilumab
  • Eosinophilic pneumonia
  • Eosinophils
  • Fiberoptic bronchoscopy
  • Monoclonal antibodies
  • Severe asthma

ASJC Scopus subject areas

  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Chemical Health and Safety

Cite this

A case of chronic eosinophilic pneumonia in a patient treated with dupilumab. / Menzella, Francesco; Montanari, Gloria; Patricelli, Giulia; Cavazza, Alberto; Galeone, Carla; Ruggiero, Patrizia; Bagnasco, Diego; Facciolongo, Nicola.

In: Therapeutics and Clinical Risk Management, Vol. 15, 01.01.2019, p. 869-875.

Research output: Contribution to journalArticle

Menzella, Francesco ; Montanari, Gloria ; Patricelli, Giulia ; Cavazza, Alberto ; Galeone, Carla ; Ruggiero, Patrizia ; Bagnasco, Diego ; Facciolongo, Nicola. / A case of chronic eosinophilic pneumonia in a patient treated with dupilumab. In: Therapeutics and Clinical Risk Management. 2019 ; Vol. 15. pp. 869-875.
@article{e6fe9992cf6e4b2ca7ef0467f65d968a,
title = "A case of chronic eosinophilic pneumonia in a patient treated with dupilumab",
abstract = "The increasing knowledge on inflammatory pathways has driven the development of targeted biological therapies for severe refractory asthma. Among the recently developed biologics, the fully human monoclonal antibody dupilumab is an interesting therapeutic option, given its ability to inhibit the biological effects of both IL-4 and IL-13. We describe the case of a male, Caucasian, 56-year-old patient with allergic and eosinophilic severe asthma. Given the poor asthma control, he started treatment with add-on dupilumab, and after the tenth injection, he presented with a fever and bilateral pulmonary thickening. A significant increase in blood eosinophilia was also reported. The patient underwent a fiberoptic bronchoscopy with bronchoalveolar lavage (BAL) and transbronchial lung biopsy (TBLB/TBB). BAL revealed eosinophils alveolitis (60{\%}) while TBB showed findings compatible with chronic eosinophilic pneumonia (CEP). After prolonged treatment with oral corticosteroids, the clinical picture improved with resolution of CEP. Since the beginning of dupilumab treatment, simultaneously to a great improvement in asthma control, the patient showed a progressive increase in blood eosinophils count and subsequent onset of clinical-radiological pattern suggestive of CEP. Based on published data, dupilumab may have induced an alteration of the complex immunological pathway of our patient. This pathway is affected by both allergic and eosinophilic asthmatic endotypes, and consequently, the concomitant action of allergenic stimuli and eosinophils may have caused the appearance of eosinophilic pneumonia. To our knowledge, this is the first reported case of CEP as a possible severe side effect of dupilumab administration.",
keywords = "Dupilumab, Eosinophilic pneumonia, Eosinophils, Fiberoptic bronchoscopy, Monoclonal antibodies, Severe asthma",
author = "Francesco Menzella and Gloria Montanari and Giulia Patricelli and Alberto Cavazza and Carla Galeone and Patrizia Ruggiero and Diego Bagnasco and Nicola Facciolongo",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/TCRM.S207402",
language = "English",
volume = "15",
pages = "869--875",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - A case of chronic eosinophilic pneumonia in a patient treated with dupilumab

AU - Menzella, Francesco

AU - Montanari, Gloria

AU - Patricelli, Giulia

AU - Cavazza, Alberto

AU - Galeone, Carla

AU - Ruggiero, Patrizia

AU - Bagnasco, Diego

AU - Facciolongo, Nicola

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The increasing knowledge on inflammatory pathways has driven the development of targeted biological therapies for severe refractory asthma. Among the recently developed biologics, the fully human monoclonal antibody dupilumab is an interesting therapeutic option, given its ability to inhibit the biological effects of both IL-4 and IL-13. We describe the case of a male, Caucasian, 56-year-old patient with allergic and eosinophilic severe asthma. Given the poor asthma control, he started treatment with add-on dupilumab, and after the tenth injection, he presented with a fever and bilateral pulmonary thickening. A significant increase in blood eosinophilia was also reported. The patient underwent a fiberoptic bronchoscopy with bronchoalveolar lavage (BAL) and transbronchial lung biopsy (TBLB/TBB). BAL revealed eosinophils alveolitis (60%) while TBB showed findings compatible with chronic eosinophilic pneumonia (CEP). After prolonged treatment with oral corticosteroids, the clinical picture improved with resolution of CEP. Since the beginning of dupilumab treatment, simultaneously to a great improvement in asthma control, the patient showed a progressive increase in blood eosinophils count and subsequent onset of clinical-radiological pattern suggestive of CEP. Based on published data, dupilumab may have induced an alteration of the complex immunological pathway of our patient. This pathway is affected by both allergic and eosinophilic asthmatic endotypes, and consequently, the concomitant action of allergenic stimuli and eosinophils may have caused the appearance of eosinophilic pneumonia. To our knowledge, this is the first reported case of CEP as a possible severe side effect of dupilumab administration.

AB - The increasing knowledge on inflammatory pathways has driven the development of targeted biological therapies for severe refractory asthma. Among the recently developed biologics, the fully human monoclonal antibody dupilumab is an interesting therapeutic option, given its ability to inhibit the biological effects of both IL-4 and IL-13. We describe the case of a male, Caucasian, 56-year-old patient with allergic and eosinophilic severe asthma. Given the poor asthma control, he started treatment with add-on dupilumab, and after the tenth injection, he presented with a fever and bilateral pulmonary thickening. A significant increase in blood eosinophilia was also reported. The patient underwent a fiberoptic bronchoscopy with bronchoalveolar lavage (BAL) and transbronchial lung biopsy (TBLB/TBB). BAL revealed eosinophils alveolitis (60%) while TBB showed findings compatible with chronic eosinophilic pneumonia (CEP). After prolonged treatment with oral corticosteroids, the clinical picture improved with resolution of CEP. Since the beginning of dupilumab treatment, simultaneously to a great improvement in asthma control, the patient showed a progressive increase in blood eosinophils count and subsequent onset of clinical-radiological pattern suggestive of CEP. Based on published data, dupilumab may have induced an alteration of the complex immunological pathway of our patient. This pathway is affected by both allergic and eosinophilic asthmatic endotypes, and consequently, the concomitant action of allergenic stimuli and eosinophils may have caused the appearance of eosinophilic pneumonia. To our knowledge, this is the first reported case of CEP as a possible severe side effect of dupilumab administration.

KW - Dupilumab

KW - Eosinophilic pneumonia

KW - Eosinophils

KW - Fiberoptic bronchoscopy

KW - Monoclonal antibodies

KW - Severe asthma

UR - http://www.scopus.com/inward/record.url?scp=85071609934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071609934&partnerID=8YFLogxK

U2 - 10.2147/TCRM.S207402

DO - 10.2147/TCRM.S207402

M3 - Article

VL - 15

SP - 869

EP - 875

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

ER -